// App-Quantinova.ai

S292 : SUSTAINED RESPONSE OFF TREATMENT IN ELTROMBOPAG-TREATED PATIENTS WITH ITP WHO ARE REFRACTORY OR RELAPSED AFTER FIRST-LINE STEROIDS: PRIMARY ANALYSIS OF THE PHASE II TAPER TRIAL

Researchers

Presenter

  • Nichola Cooper

Principal Investigators

  • Waleed Ghanima

  • Nicola Vianelli

  • David Valcrcel

  • Irfan Yavasoglu

  • Anait Melikyan

  • Jens Haenig

  • James Lee

  • Joan Maier

  • Francesco Zaja

Medical Centers

  • Hematology-Oncology Unit, Department of Internal Medicine, School of Medicine,Universidad de la Frontera,Temuco,Chili

  • IQVIA,St. Petersburg,Russische Federatie

  • Hematology-Oncology Unit, Department of Internal Medicine, School of Medicine,Universidad de la Frontera,Temuco,Chili

  • Department of Medicine,Østfold Hospital Trust,Kalnes,Noruega

  • Novartis Pharmaceuticals Corporation East Hanover NJ United States

  • National Research Center for Hematology, Moscow, Russia

  • IQVIA,St. Petersburg,Russie, Fédération De

  • Department of Medical, Surgical and Health S

  • Department of Medicine,Østfold Hospital Trust,Kalnes,Noruega

  • National Research Center for Hematology, Moscow, Russia

  • Department I

  • Novartis Pharmaceuticals AG,Basel,Швейцария

  • Novartis Pharmaceuticals Corporation East Hanover NJ United States

  • Novartis Pharma Corp, Basel, Switzerland

  • Department of Medical and Surgical Sciences,University of Trieste,Trieste,Italy

  • Novartis Pharma AG,Basel,Svizzera

  • National Research Center for Hematology, Moscow, Russia

  • Hematology-Oncology Unit, Department of Interna

  • Centre for Haematology, Department of Immunology and Inflammation,Imperial College London, Hammersmith Hospital,London,Vereinigtes Königreich

  • Department of Hematology,Adnan Menderes University,Aydın,Turkey

  • Department of Hematology,Adnan Menderes University,Aydın,Turkey

  • Novartis Pharma AG,Basel,Zwitserland

  • Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain

  • IQVIA,St. Petersburg,Россия

  • Centre for Haematology, Department of Immunology and Inflammation,Imperial College London, Hammersmith Hospital,London,Vereinigtes Königreich

  • Department of Medicine,Østfold Hospital Trust,Kalnes,Noruega

  • Scientific Institute for Research, Hospitalization and Healthcare (IRCCS),Azienda Ospedaliero-Universitaria di Bologna,Bologna,Italie

  • Department of Medical and Surgical Sciences,University of Trieste,Trieste,Italy

  • Hematology-Oncology Unit, Department of Internal Medicine, School of Medicine,Universidad de la Frontera,Temuco,Chili

  • Department of Medicine,Østfold

  • Surgery department,National Research Center for Hematology,Moscow,Russie, Fédération De

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • IQVIA,St. Petersburg,Russia

  • IQVIA,St. Petersburg,Russia

  • Department of Hematology,Adnan Menderes University,Aydın,Turkey

  • Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain

  • Department of Medicine,Østfold Hospital Trust,Kalnes,Noruega

  • Department of Medicine,Østfold Hospital Trust,Kalnes,Noruega

  • Department of Medical and Surgical Sciences,University of Trieste,Trieste,Italy

  • Scientific Institute for Research, Hospitalization and Healthcare (IRCCS),Azienda Ospedaliero-Universitaria di Bologna,Bologna,Italie

  • Department of Hematology,Adnan Menderes University,Aydın,Turkey

  • Department of Hematology,Adnan Menderes University,Aydın,Turkey

  • Novartis Pharma AG,Basel,Svizzera

  • Department of Hematology,Vall d'Hebron

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain

  • Department of Hematology,Adnan Menderes University,Aydın,Turkey

  • National Research Center for Hematology, Moscow, Russia

  • Department of Medicine,Østfold Hospital Trust,Kalnes,Noruega

  • Department of Medical and Surgical Sciences,University of Trieste,Trieste,Italy

  • Novartis Pharma AG,Basel,Svizzera

  • Novartis Pharma AG,Basel,Svizzera

  • Scientific Institute for Research, Hospitalization and Healthcare (IRCCS),Azienda Ospedaliero-Universitaria di Bologna,Bologna,Italie

  • Novartis Pharma AG,Basel,Svizzera

  • Centre for Haematology, Department of Immunology and Inflammation,Imperial College London, Hammersmith Hospital,London,Vereinigtes Königreich

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis Pharmaceuticals Corporation,East Hanover,Estados Unidos

Locations

  • United Kingdom

  • Norway

  • Italy

  • Palestine

  • United States

  • Turkey

  • Russia

  • Chile

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Eltrombopag

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03524612

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved